AAAAAA

   
Results: 1-8 |
Results: 8
The UL41-encoded virion host shutoff (vhs) protein and vhs-independent mechanisms are responsible for down-regulation of MHC class I molecules by bovine herpesvirus 1
Authors: Koppers-Lalic, D Rijsewijk, FAM Verschuren, SBE van Gaans-van den Brink, JAM Neisig, A Ressing, ME Neefjes, J Wiertz, EJHJ
Citation: D. Koppers-lalic et al., The UL41-encoded virion host shutoff (vhs) protein and vhs-independent mechanisms are responsible for down-regulation of MHC class I molecules by bovine herpesvirus 1, J GEN VIROL, 82, 2001, pp. 2071-2081
Natural T-HELPER immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes
Authors: van der Burg, SH Ressing, ME Kwappenberg, KMC de Jong, A Straathof, K de Jong, J Geluk, A van Meugaarden, KE Franken, KLMC Ottenhoff, THM Fleuren, GJ Kenter, G Melief, CJM Offringa, R
Citation: Sh. Van Der Burg et al., Natural T-HELPER immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes, INT J CANC, 91(5), 2001, pp. 612-618
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
Authors: Ressing, ME van Driel, WJ Brandt, RMP Kenter, GG de Jong, JH Bauknecht, T Fleuren, GJ Hoogerhout, P Offringa, R Sette, A Celis, E Grey, H Trimbos, BJ Kast, WM Melief, CJM
Citation: Me. Ressing et al., Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma, J IMMUNOTH, 23(2), 2000, pp. 255-266
Peptides in cervical cancer
Authors: Ressing, ME Brandt, RMP de Jong, JH Offringa, R Melief, CJM Kast, WM
Citation: Me. Ressing et al., Peptides in cervical cancer, MED INTEL U, 24, 2000, pp. 172-189
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
Authors: van Driel, WJ Ressing, ME Kenter, GG Brandt, RMP Krul, EJT van Rossum, AB Schuuring, E Offringa, R Bauknecht, T Tamm-Hermelink, A van Dam, PA Fleuren, GJ Kast, WM Melief, CJM Trimbos, JB
Citation: Wj. Van Driel et al., Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial, EUR J CANC, 35(6), 1999, pp. 946-952
Differential binding of viral peptides to HLA-A2 alleles. Implications forhuman papillomavirus type 16 E7 peptide-based vaccination against cervicalcarcinoma
Authors: Ressing, ME de Jong, JH Brandt, RMP Drijfhout, JW Benckhuijsen, WE Schreuder, GMT Offringa, R Kast, WM Melief, CJM
Citation: Me. Ressing et al., Differential binding of viral peptides to HLA-A2 alleles. Implications forhuman papillomavirus type 16 E7 peptide-based vaccination against cervicalcarcinoma, EUR J IMMUN, 29(4), 1999, pp. 1292-1303
T-cell-mediated immunotherapy of cancer
Authors: Offringa, R Toes, REM Ressing, ME de Bruijn, MLH Melief, CJM
Citation: R. Offringa et al., T-cell-mediated immunotherapy of cancer, TEXTBOOK OF MALIGNANT HAEMATOLOGY, 1999, pp. 447-461
Antitumor vaccination using peptide-based vaccines
Authors: Offringa, R Toes, REM Ressing, ME Vierboom, MPM Ossendorp, F Van der Burg, SH Nijman, HW Kast, WM Melief, CJM
Citation: R. Offringa et al., Antitumor vaccination using peptide-based vaccines, RESEARCH IN, 1998, pp. 205-215
Risultati: 1-8 |